Stay updated on Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Sign up to get notified when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.

Latest updates to the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check19 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check27 days agoChange DetectedA sitewide NIH banner announces a website transition and says “Super Intelligence” is being used in place of “Artificial Intelligence” during the transition.SummaryDifference0.8%

- Check33 days agoChange DetectedThe site footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.1%

- Check40 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, reflecting a site software update.SummaryDifference0.1%

- Check61 days agoChange DetectedA new revision entry (v3.7.0) was added to the study record history, and the previous revision (v3.6.6) was removed from the current history view.SummaryDifference0.1%

- Check83 days agoChange DetectedRecord history shows the page version updated from v3.6.5 to v3.6.6, indicating an internal revision of the history page. This is an administrative update and does not modify study details.SummaryDifference0.1%

Stay in the know with updates to Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.